Not too much estrogen. Not too little androgen. The aromatase enzyme tipping the scale in adipose tissue. This is the mechanism boards are testing.
The Core Mechanism
The Tilting Scale
Gynecomastia is not about estrogen being high. It is about the ratio shifting. Watch what aromatase does.
Chapter 1 of 3 · The Setup
Carlos, 48
Bilateral breast fullness. BMI 38. No meds, no liver disease. His estradiol is mildly elevated. His testosterone is low-normal. Something is tipping his ratio.
The fat around his torso is the culprit.
It is loaded with aromatase enzyme.
PatternMore fat = more aromatase = more estrogen relative to androgen = breast tissue grows
PearlGynecomastia = E:A ratio problem. The engine is aromatase in fat. Adrenal androgen synthesis is not the mechanism.
CarlosBMI 38 + mildly elevated estradiol + no drugs/liver disease = obesity-driven aromatase. His adrenals are fine. His fat did this.
Board Challenge
Answer Before You Continue
Opener Challenge
A 48-year-old man with BMI 38 presents with bilateral breast fullness that has grown progressively over 18 months. He takes no medications, denies alcohol use, and has no signs of liver disease. Serum estradiol is mildly elevated. Testosterone is low-normal. Thyroid function tests are normal. A careful history reveals his father had a similar chest appearance in his 60s.
Which mechanism most likely explains this patient's breast tissue enlargement?
ADecreased adrenal androgen synthesistap to expand
Good instinct. If androgens drop, the E:A ratio shifts toward estrogen, and that sounds right. But think about it like a dimmer switch vs a converter box. Adrenal androgen synthesis dropping would be like turning down the dimmer a little. Aromatase in adipose is the converter box actively churning androgens into estrogens. In obesity, it is not that the adrenals are broken -- it is that the fat is working overtime converting what is there. No evidence of adrenal insufficiency, no Addisonian features, no reason to blame the adrenals here. Break it down: The adrenal glands are fine. The fat is the factory. Decreased adrenal synthesis is NOT the mechanism of obesity-related gynecomastia.
BIncreased peripheral aromatase activityCORRECT
This is exactly right. Adipose tissue is loaded with aromatase enzyme, which converts androstenedione and testosterone into estrone and estradiol. The more fat, the more aromatase, the more estrogen relative to androgen. BMI 38 is significant obesity. This man's fat tissue is running a quiet estrogen factory. His testosterone is low-normal partly because estrogen suppresses the HPG axis, further worsening the ratio. Father had it too because obesity runs in families. Break it down: Increased peripheral aromatase activity in adipose tissue = the anchor mechanism of obesity-driven gynecomastia. Lock it.
CDecreased hepatic estrogen clearancetap to expand
Cirrhosis does impair hepatic estrogen metabolism and can cause gynecomastia -- but this patient has no signs of liver disease. The stem specifically says no signs of liver disease. Decreased clearance is a real mechanism in cirrhosis patients with spider angiomas, jaundice, and elevated bilirubin. Without those clues, you should not reach for the liver. Think about where estrogen comes from (aromatase) before you worry about where it goes (the liver). Break it down: Decreased hepatic clearance = cirrhosis pattern. No liver disease here. Wrong context.
DDecreased sex hormone-binding globulintap to expand
Think about what low SHBG would do. SHBG binds both testosterone and estradiol. If SHBG drops, more of both are free. That could raise free estrogen, yes -- but it raises free testosterone equally. The ratio does not necessarily shift toward estrogen. Also, obesity tends to lower SHBG (which is why obese men can have low total testosterone but adequate free testosterone), so this is partially true but does not explain the gynecomastia mechanism specifically. Aromatase is the direct driver. Break it down: Decreased SHBG does not selectively raise estrogen. It is not the gynecomastia mechanism here.
EIncreased testicular estrogen productiontap to expand
The testes can produce some estradiol directly, but this is a minor contribution. The primary source of elevated estrogen in an obese man is peripheral conversion by aromatase -- not the testes making more. If the testes were directly secreting excess estrogen, you would be looking at a testicular germ cell tumor or a Sertoli cell tumor. No testicular mass is mentioned here. Break it down: Increased testicular estrogen = tumor scenario. No tumor, no testicular pathology. This is adipose aromatase.
Clue chain: obese middle-aged man (BMI 38) + bilateral breast fullness + no liver disease + no drugs + mildly elevated estradiol = aromatase factory in adipose tissue converting androgens to estrogens. Obese father same pattern = familial adiposity driving aromatase. The adrenal glands are innocent. The fat is the culprit.
1 / 6
The Causes
Cause Lineup
Four categories. Three are true gynecomastia. One is the impostor that is NOT gynecomastia at all. Tap each to flip.
🚾
Physiologic
Normal life stages
Neonatal · Pubertal · Senescent
Three windows when the ratio naturally shifts. Does not need treatment. Usually resolves.
tap for the three windows →
Physiologic Gynecomastia
Neonatal: maternal estrogens cross placenta; resolves in weeks
Pubertal (13-14y): estrogens rise before testosterone peaks; transient, bilateral, resolves by 17
Anabolic steroids: peripheral aromatization of exogenous androgens → estradiol surge
Board tip: Spironolactone in HF patient + gynecomastia = classic board vignette. Use eplerenone instead (selective, no AR blockade).
⚠️
Male Breast Cancer
THE IMPOSTOR
Hard · Eccentric · Fixed
This is NOT gynecomastia. Three features distinguish it immediately on exam.
tap to learn the kill features →
Male Breast Cancer vs Gynecomastia
Gynecomastia: soft-rubbery, concentric disc under areola, bilateral (usually), tender
Cancer:hard, non-tender, eccentric (off-center), fixed to skin/chest wall
Cancer red flags: nipple retraction, skin dimpling, axillary lymphadenopathy, unilateral
Most common in BRCA2 mutation carriers; also Klinefelter association
Board kill: Hard + eccentric + fixed = biopsy, not reassurance. Never dismiss unilateral hard masses as gynecomastia.
⚠Pseudogynecomastia (lipomastia) is a third entity: soft, diffuse, uniform fatty breast tissue with NO central glandular disc under the areola. Seen in obesity. The distinction from true gynecomastia is made by palpation alone. No biopsy needed.
2 / 6
The Detective Trail
Three-Step Diagnostic Walkthrough
Answer before each step reveals. Answer wrong and you stay on it. Answer right to advance.
Step 1 of 3 · Physical Exam First
A 54-year-old man with BMI 43 presents with bilateral breast enlargement. You palpate under the right areola. What finding distinguishes true gynecomastia from pseudogynecomastia?
Symmetric appearance on inspection does not distinguish them. Both can look bilateral and symmetric. The difference is under your fingers, not in the mirror. Go back and palpate.
Exactly. True gynecomastia = a firm, rubbery, concentric disc of glandular tissue centered directly under the areola. Pseudogynecomastia = soft, diffuse, fatty without a central disc. You cannot tell the difference by looking. You have to palpate. This one physical exam finding directs everything downstream.
Tenderness can occur in both, especially in active physiologic gynecomastia. It does not distinguish the two entities. The tissue character under the areola does.
A lab value does not replace physical exam here. Pseudogynecomastia is a physical exam diagnosis. Estradiol might be normal in either. Palpate first, labs later.
Step 2 of 3 · Is This Physiologic?
A 14-year-old male brought in by his mother for bilateral tender breast tissue. He is at Tanner stage III. His father reports the same thing happened to him at 14 and resolved by 17. Height and weight are appropriate. No medications, no alcohol, no other symptoms.
What is the most appropriate management?
You do not need a hormone panel for a Tanner III 14-year-old with a positive family history of the same course. Bilateral, symmetric, pubertal, with appropriate development = physiologic. Labs are reserved for atypical presentations: prepubertal, unilateral, no family history, with testicular mass, or not resolving by 17.
Right. Pubertal gynecomastia is the most common cause of breast tissue in male teenagers. It results from a transient rise in estrogens during early puberty before testosterone fully surges. Family history of the same course is the final reassurance. Watchful waiting is the standard. It resolves spontaneously in most boys by age 16 to 17. No drugs, no surgery, no labs needed.
Surgery is not indicated for physiologic pubertal gynecomastia. The criteria for referral require persistence beyond 17, significant psychological distress despite counseling, or macromastia causing physical symptoms. This boy has a classic, expected pubertal course.
Tamoxifen can be used in severe, persistent cases, but it is not first-line for a 14-year-old with a classic pubertal presentation and a positive family history of resolution. Overtreatment here.
Step 3 of 3 · Kill the Distractor
A 52-year-old man with obesity (BMI 36), no medications, no liver disease, and normal thyroid function presents with progressive bilateral breast tissue enlargement over 2 years. Serum estradiol is mildly elevated. Testosterone is low-normal. No testicular mass. No adrenal mass on imaging.
Which mechanism most directly drives this patient's gynecomastia?
This is the anchor distractor. It feels right because: if androgens drop, the ratio shifts toward estrogen. But the adrenal glands are not failing here. There is no evidence of adrenal insufficiency. No hypotension, no hyperpigmentation, no hyperkalemia, no fatigue from cortisol loss. Decreased adrenal androgen synthesis would be Addison disease or CAH territory. In obesity, the adrenal glands are producing androgens just fine -- the fat is converting them. The distractor targets your reflex to think "low A = gynecomastia" without specifying the mechanism. Break it down: Adrenal androgen synthesis is NOT reduced in obesity-driven gynecomastia.
There it is. This is the answer the board question was built to test. Obesity loads adipose tissue with aromatase enzyme. Aromatase converts circulating androgens (androstenedione, testosterone) into estrogens (estrone, estradiol). More adipose = more aromatase = more estrogen production = rising E:A ratio = gynecomastia. The testosterone being low-normal is partly the consequence: rising estrogen feeds back to suppress the HPG axis, reducing testosterone output, further tipping the ratio. The adrenal glands did not cause this. The fat did.
Decreased hepatic clearance of estrogens is real -- in cirrhosis. The liver normally metabolizes estrogens. When the liver fails, estrogens accumulate. But this patient has no liver disease. The mechanism that applies to cirrhosis does not apply here. Know your context: cirrhosis patient = think hepatic clearance. Obese man with no liver disease = think aromatase.
Primary hypogonadism (testicular failure) causes gynecomastia by reducing testosterone output, shifting the E:A ratio by subtraction on the androgen side. Classic examples are Klinefelter syndrome (47,XXY), mumps orchitis, or radiation. This patient has no testicular mass, no small testes mentioned, and his testosterone is low-normal (not frankly low as in primary hypogonadism). Primary hypogonadism = markedly low testosterone + elevated FSH/LH. That is not this picture.
3 / 6
The Memory Bank
Four Hooks to Lock It
Tap each card to reveal the payoff. Blur is your retrieval practice.
Mechanism Hook
The adrenals are innocent. The fat is the factory.
In obesity-related gynecomastia, adrenal androgen synthesis is normal. The problem is downstream: adipose tissue is packed with aromatase enzyme that converts adrenal androgens (androstenedione) and gonadal androgens (testosterone) into estrogens. The fat does not reduce androgens -- it converts them. "Decreased adrenal androgen synthesis" is the #1 distractor on boards because it sounds like it would shift the ratio, but it is NOT what happens in obesity. The fat is the aromatase factory. Blame the fat, not the adrenals.
tap to reveal
Physiologic Windows Hook
Three ages when gynecomastia is normal: New. Teen. Old.
Neonatal: maternal estrogens cross the placenta. Resolves in weeks. No treatment.
Pubertal (13 to 14): estrogens peak before testosterone does. Bilateral, tender, resolves by 16 to 17. Reassure. No labs needed for a classic picture with family history.
Senescent (over 60): testosterone production falls as Leydig cells age, adipose increases with age, aromatase upregulation adds to it. The ratio tilts slowly. This is why grandfathers sometimes develop breast tissue.
"New. Teen. Old." = the three physiologic windows.
tap to reveal
Drug Trap Hook
Spiro blocks the androgen receptor. Keto kills testosterone synthesis. Cimeti blocks the receptor. Anabolics fuel the aromatase.
Spironolactone: androgen receptor antagonist + inhibits 17-hydroxylase (reduces testosterone synthesis). Double hit.
Ketoconazole: antifungal that blocks adrenal and testicular CYP enzymes (17,20-lyase). Testosterone drops.
Cimetidine (H2 blocker): androgen receptor antagonist. Classically causes gynecomastia in peptic ulcer patients. Use famotidine or a PPI to avoid this.
Anabolic steroids: exogenous testosterone floods aromatase enzyme in peripheral tissues. Estradiol spikes. Body builders learn this the hard way.
Board swap: spironolactone causing gynecomastia in HF? Switch to eplerenone (selective mineralocorticoid, no AR block).
tap to reveal
Cancer Kill Hook
Hard. Eccentric. Fixed. Lymphadenopathy. Biopsy. Full stop.
Gynecomastia is soft and rubbery, centered directly under the areola (concentric), bilateral in most cases, and often tender.
Male breast cancer is hard and non-tender, located away from the areola center (eccentric), fixed to the skin or chest wall, and associated with nipple retraction, skin dimpling, and axillary nodes.
The one-line rule: if a male breast mass is hard, eccentric, or fixed -- it is cancer until proven otherwise. Do NOT reassure. Do NOT watch and wait. Order imaging and biopsy.
BRCA2 is the most common genetic association for male breast cancer. Klinefelter syndrome also increases risk.
tap to reveal
4 / 6
Clinical Gallery
Recognize the Context
Tap any image to expand with the teaching caption.
Gynecomastia · bilateral glandular tissue
Cirrhosis · decreased hepatic estrogen clearance
Spironolactone · androgen receptor blocker
Adipose tissue · the aromatase factory
Clinical GynecomastiaBilateral subareolar glandular tissue enlargement in a male. True gynecomastia is distinguished from pseudogynecomastia (lipomastia) by palpation: a firm, concentric, rubbery disc of glandular tissue directly beneath the areola. If soft and diffuse without a central disc, it is fatty tissue only.Wikimedia Commons · Public Domain
Cirrhosis · Pathologic GynecomastiaIn cirrhosis, the failing liver cannot metabolize estrogens efficiently. Estrogens accumulate. Additionally, peripheral aromatase activity is upregulated in chronic liver disease. The result: elevated free estradiol, suppressed testosterone, and a shifted E:A ratio. Look for spider angiomas, palmar erythema, jaundice, and caput medusae alongside the gynecomastia. This is a different mechanism from obesity-driven aromatase -- it is impaired clearance, not excess production.Wikimedia Commons · CC BY-SA 3.0
Spironolactone · Drug-Induced GynecomastiaSpironolactone is a mineralocorticoid receptor antagonist used in heart failure, hyperaldosteronism, and resistant hypertension. Its side effect of gynecomastia comes from two mechanisms: it blocks the androgen receptor directly, and it inhibits testosterone synthesis at 17-hydroxylase. The result is a double drop in androgen activity with estrogen unopposed. Switch to eplerenone (selective mineralocorticoid antagonist, no AR blockade) when gynecomastia becomes problematic.Wikimedia Commons · Public Domain
Adipose Tissue · The Aromatase FactoryLarge vacuolated adipocytes are the primary site of peripheral aromatization in men. Adipose tissue expresses CYP19A1 (aromatase), which converts androstenedione to estrone and testosterone to estradiol. The more adipose tissue (obesity, aging), the greater the aromatase activity. This is why obesity and advancing age are the two most common physiologic drivers of gynecomastia in adult men. The adrenal glands and testes are still producing androgens normally -- the fat is just converting them.Wikimedia Commons · Public Domain
5 / 6
Board Walkthrough
Five Patients. One Mechanism Tested Five Ways.
The same concept -- the E:A ratio -- shows up in different clinical wrapping. Work through each patient before the explanations reveal.
Board Vignette · 1 of 5
A 62-year-old man with heart failure on spironolactone 100 mg daily for 3 years presents with bilateral breast tenderness and enlargement. Serum testosterone is low-normal. Estradiol is mildly elevated. Thyroid function is normal. He has no signs of liver disease.
Which mechanism best explains this patient's gynecomastia?
AIncreased peripheral aromatase from obesitytap to expand
Good anchor instinct -- aromatase is your gynecomastia default. But this patient is on spironolactone. The drug has a more direct mechanism than aromatase here. Aromatase would be your answer for an obese man with no medications. When a medication is named in the stem, it is usually the mechanism they are testing. Break it down: When a drug is in the stem, the drug is the mechanism. Aromatase is the obesity mechanism, not the spironolactone mechanism.
BAndrogen receptor blockade by the medicationCORRECT
Spironolactone does two things to the androgen side of the E:A ratio. First, it blocks the androgen receptor directly, so testosterone cannot signal even if it is present. Second, it inhibits the 17-hydroxylase enzyme in the adrenal and testes, reducing testosterone synthesis. Both actions reduce androgen effect. Estrogen goes unopposed. Breast tissue grows. This is the classic board vignette: HF patient on spiro develops gynecomastia. The fix is switching to eplerenone, which is a selective mineralocorticoid antagonist without the AR-blocking side effect. Break it down: Spironolactone = androgen receptor antagonist + testosterone synthesis inhibitor. Classic iatrogenic gynecomastia.
CDecreased hepatic estrogen clearancetap to expand
The stem specifically says no signs of liver disease. Hepatic congestion from heart failure can cause mild transaminase elevations, but it does not cause clinically significant impairment of estrogen metabolism. You need cirrhosis for that. Grab the most direct mechanism: the drug is in the stem. Break it down: No liver disease in the stem = do not reach for hepatic clearance. The drug did this.
DTesticular estrogen oversecretiontap to expand
Testicular estrogen oversecretion happens with hCG-secreting tumors that drive Leydig cells to produce excess estradiol. That is a tumor story: elevated hCG, testicular mass, young man. Not an older HF patient on spiro. Break it down: Testicular estrogen = tumor story (hCG-secreting germ cell tumor). Not the spironolactone story.
EDecreased adrenal androgen synthesistap to expand
Spironolactone does inhibit adrenal steroidogenesis (17-hydroxylase), so this is partially true. But the question is asking for the best mechanism, and androgen receptor blockade is the more direct and complete answer. Spiro blocks the receptor AND reduces synthesis. The receptor block is the primary clinical driver of its gynecomatia side effect. Break it down: Adrenal synthesis inhibition is partial -- AR blockade is the complete and primary spironolactone mechanism.
Key chain: drug named + bilateral breast tissue + low-normal testosterone = drug is blocking the androgen receptor. Spironolactone is the #1 drug cause on boards. The fix: eplerenone. The mechanism: androgen receptor antagonism.
Board Vignette · 2 of 5
A 22-year-old male presents with a 3-month history of painless right testicular swelling and bilateral gynecomastia. He is otherwise healthy. Serum beta-hCG is markedly elevated at 31,400 mIU/mL. Testicular ultrasound shows a 3 cm heterogeneous intratesticular mass with increased vascularity.
What is the most likely mechanism of gynecomastia in this patient?
AMass effect reducing androgen synthesistap to expand
A mass compressing the testis could reduce testosterone output, yes. But that would lower androgens -- and low androgens do shift the ratio toward estrogen. However, the massive hCG level (31,400 mIU/mL) is a flashing neon sign pointing at a completely different and more powerful mechanism. The hCG is not a bystander here. It is driving the whole picture. Do not ignore a strikingly abnormal lab value to reach for a mechanical explanation. Break it down: The hCG is the mechanism. Do not explain away a 31,000 hCG as "mass effect."
BhCG stimulating Leydig cells to produce excess estradiolCORRECT
hCG is structurally similar to LH. When a germ cell tumor (choriocarcinoma or mixed nonseminomatous germ cell tumor) secretes massive amounts of hCG, it hits the LH receptor on testicular Leydig cells. Those Leydig cells respond by ramping up estradiol production beyond what they would normally make. Estradiol rises dramatically, androgens do not keep pace, and the E:A ratio swings hard toward estrogen. Gynecomastia follows. This is the high-yield testicular tumor + gynecomastia pathway. Young man + painless testicular mass + elevated hCG + gynecomastia = germ cell tumor with hCG-driven Leydig stimulation. hCG acts like LH on Leydig cells. Excess estradiol secretion. E:A ratio crashes. Classic germ cell tumor presentation.
CIncreased peripheral aromatasetap to expand
Aromatase is the mechanism for an obese, middle-aged, medication-free man. This patient is 22, presumably not morbidly obese, and has a testicular mass with hCG 31,000. Peripheral aromatase does not explain the hCG, the mass, or the acute 3-month course. The tumor is doing something much more direct. Break it down: Aromatase = obesity mechanism. Not the germ cell tumor mechanism. The hCG is telling you exactly where to look.
DHepatic metastases reducing estrogen clearancetap to expand
There are no hepatic metastases mentioned. You cannot assume metastases to explain a finding when the primary tumor is sitting right there in the scrotum doing exactly what the hCG says it is doing. Even if this tumor did metastasize to the liver, the dominant mechanism would still be hCG-driven Leydig stimulation given the hCG level. Break it down: Do not invent hepatic mets that are not in the stem. The hCG is the mechanism. Leydig stimulation. Estradiol oversecretion.
Clue chain: young man + painless testicular mass + markedly elevated hCG + gynecomastia = germ cell tumor (likely choriocarcinoma or mixed). hCG activates LH receptors on Leydig cells. Excess estradiol. Gynecomastia. The hCG and the testicular mass together lock this answer.
Board Vignette · 3 of 5
A 19-year-old male is evaluated for infertility concerns, bilateral gynecomastia, and small firm testes. He is 6 feet 4 inches tall with a eunuchoid habitus. Serum FSH and LH are markedly elevated. Testosterone is low. Karyotype shows 47,XXY.
What is the primary mechanism of gynecomastia in this patient?
AIncreased peripheral aromatasetap to expand
The obesity-aromatase mechanism is for an adult man with no karyotype abnormalities, no small testes, and normal FSH/LH. This patient has small testes, an XXY karyotype, high FSH/LH, and low testosterone. The testicles are simply not producing testosterone because they are dysgenetic (the extra X chromosome derails normal Sertoli and Leydig cell function). The E:A ratio shifts by subtraction on the androgen side -- not by aromatase excess. Break it down: Aromatase = obesity. Klinefelter gynecomastia = primary gonadal failure. Different mechanism, different patient.
BPrimary gonadal failure with low testosteroneCORRECT
Klinefelter syndrome (47,XXY) causes primary hypogonadism. The testes are dysgenetic -- they cannot produce normal amounts of testosterone. With testosterone chronically low, the E:A ratio shifts toward estrogen by default. The pituitary senses low testosterone and drives FSH and LH sky-high trying to compensate. But the dysgenetic testes cannot respond. Gynecomastia, infertility, small testes, tall stature (the extra X delays epiphyseal closure), and eunuchoid habitus are the clinical package. 47,XXY = primary hypogonadism = low testosterone = E:A ratio tilts toward estrogen by subtraction on the androgen side.
CDecreased hepatic estrogen clearancetap to expand
Liver disease would need jaundice, elevated bilirubin, ascites, spider angiomas, or at minimum some context suggesting hepatic dysfunction. A 19-year-old with Klinefelter syndrome has normal liver function. There is nothing in this stem to implicate the liver. The karyotype explains everything. Break it down: Hepatic clearance = cirrhosis context. Normal liver in Klinefelter. Blame the testicles, not the liver.
DhCG-secreting germ cell tumortap to expand
A germ cell tumor would present with a unilateral testicular mass and elevated hCG. This patient has bilateral small firm testes, not a unilateral mass. The hCG is not mentioned as elevated. The karyotype is 47,XXY, which directly explains the entire clinical picture. When the karyotype is handed to you in the stem, it is the answer. Break it down: Germ cell tumor = testicular mass + elevated hCG. No mass here. The karyotype IS the diagnosis.
Clue chain: tall male + small firm testes + gynecomastia + infertility + high FSH/LH + low testosterone + 47,XXY = Klinefelter syndrome. The extra X chromosome prevents normal testicular development. Leydig cells cannot produce adequate testosterone. FSH/LH rise and get no response. E:A ratio shifts by low androgen. Gynecomastia follows.
Board Vignette · 4 of 5
A 52-year-old male alcoholic presents with fatigue, jaundice, bilateral gynecomastia, and spider angiomas over his chest. Serum bilirubin is elevated. AST:ALT ratio is 2:1. Prothrombin time is prolonged. He is on no medications.
Which mechanism is primarily responsible for the gynecomastia in this patient?
AIncreased peripheral aromatasetap to expand
Aromatase upregulation does occur in chronic liver disease. But the question is asking for the PRIMARY mechanism, and the liver failure context points most directly at impaired hepatic clearance. The clinical picture (jaundice, spider angiomas, coagulopathy, AST:ALT 2:1) is screaming liver failure at you. The liver's job of metabolizing estrogens is shut down. That is the answer they want. Break it down: Aromatase is a secondary contributor in cirrhosis. The PRIMARY mechanism is failed hepatic estrogen clearance.
BDecreased hepatic estrogen clearanceCORRECT
The liver normally metabolizes estrogens by sulfation and glucuronidation. In cirrhosis, hepatocytes are replaced by fibrotic scar. The machinery breaks down. Estrogens that would normally be inactivated and excreted accumulate in circulation. Testosterone is also affected by increased SHBG (the liver makes SHBG, but here SHBG actually changes in a complex way; the net result is lower free testosterone). Estrogen accumulates, androgen effect falls, ratio tilts, gynecomastia and spider angiomas appear. The AST:ALT of 2:1 is your alcoholic liver disease marker. Jaundice + coagulopathy + spider angiomas = liver failure doing this. Break it down: Cirrhosis = impaired hepatic estrogen clearance = estrogen accumulation = gynecomastia. Spider angiomas are just estrogen excess in the skin.
ChCG stimulating Leydig cellstap to expand
hCG-driven gynecomastia is a germ cell tumor story: young man, elevated hCG, unilateral testicular mass. This 52-year-old alcoholic with jaundice and coagulopathy is a cirrhosis story. No testicular mass is mentioned. No elevated hCG. The Leydig cells are not the problem here. The liver is. hCG mechanism = testicular tumor in a young man. Not cirrhosis in an alcoholic.
DDecreased adrenal androgen synthesistap to expand
Adrenal androgen synthesis is not primarily affected by alcoholic cirrhosis. The adrenal glands are outside this pathology. Decreased adrenal androgen synthesis would be an Addison disease or late CAH pattern with hypotension, hyperkalemia, and hyponatremia. This patient has liver-specific findings. Do not pull in a mechanism that has no evidence in the stem. Break it down: Adrenal androgen synthesis is intact in alcoholic cirrhosis. The liver is the problem. Not the adrenals.
Clue chain: alcoholic + jaundice + AST:ALT 2:1 + coagulopathy + spider angiomas + gynecomastia = alcoholic cirrhosis. The liver fails to metabolize estrogens. Estrogens accumulate. Spider angiomas (dilated arterioles driven by estrogen-mediated vasodilation) and gynecomastia appear together. This is the cirrhosis package.
Board Vignette · 5 of 5
A 67-year-old man presents with a 3-month right breast mass he describes as "getting harder." Physical exam reveals a 2 cm hard, non-tender, irregular mass at the 2 o'clock position in the right breast, eccentric to the areola. There is overlying skin thickening and a firm palpable right axillary lymph node. The left breast is normal. He has no history of medications or liver disease.
Which statement is most accurate regarding this patient's presentation?
AConsistent with senescent gynecomastiatap to expand
Good instinct to think gynecomastia in a 67-year-old -- senescent gynecomastia is real. But here is the problem: gynecomastia is soft, rubbery, concentric (under the areola), usually bilateral, and often tender. This mass is hard, non-tender, eccentric (2 o'clock position, NOT under the areola), with skin thickening and a fixed axillary node. Every single feature on that list is a cancer red flag. You cannot call this gynecomastia and go home. Break it down: Gynecomastia = soft, concentric, bilateral. This = hard, eccentric, unilateral, fixed, lymphadenopathy. Not gynecomastia.
BHard, eccentric, fixed mass with lymphadenopathy mandates biopsyCORRECT
Male breast cancer is uncommon but real. Hard, non-tender, eccentric (off-center from areola), fixed to skin or chest wall, with skin changes (thickening, dimpling) and axillary lymphadenopathy = biopsy. Full stop. Every one of these features is a red flag. The correct clinical pathway is imaging (mammogram + ultrasound) followed by core needle biopsy. Male breast cancer is most strongly associated with BRCA2 mutations. Klinefelter syndrome also increases risk. Do not reassure. Do not watch. Biopsy. Break it down: Hard + eccentric + fixed + lymphadenopathy in a male breast = biopsy, not watchful waiting. This is cancer until proven otherwise.
CUnilateral masses are almost always benigntap to expand
This is exactly the clinical pearl that gets patients harmed. Unilateral presentation raises concern, not lowers it, when combined with hardness, eccentricity, skin changes, and lymphadenopathy. Gynecomastia is usually bilateral. A unilateral hard eccentric mass with lymphadenopathy has no benign explanation. Do not apply a false reassurance stat to this presentation. Break it down: Unilateral hard eccentric mass in a male breast = cancer until proven otherwise. Never reassure without biopsy.
DMonitor for 6 months before workuptap to expand
You monitor pubertal gynecomastia in a 14-year-old with a classic bilateral tender presentation, no family history of cancer, and appropriate development. You do NOT monitor a 67-year-old with a hard, eccentric, fixed mass with skin thickening and axillary lymphadenopathy. Six months of watching this could be the difference between a stage II and stage IV cancer. The features are unambiguously concerning. Act now. Break it down: Watchful waiting is for physiologic gynecomastia. For cancer features, it is imaging and biopsy. Monitoring is never appropriate here.
Kill the confusion: the physical exam features MUST override your default "it is probably gynecomastia in an older man" thinking. Hard + eccentric + fixed + unilateral + skin changes + lymphadenopathy = cancer workup. Gynecomastia does none of those things on exam. Trust the palpation.
